AI 导读
FDA 启动一项试点项目，挑选 10 家公司以加速且互动式的审评流程，探索应如何评估药物申报中的 AI 生成证据。目前全球超过 200 款 AI 设计的药物正处于临床试验阶段，尚无一款获得 FDA 批准。作者称药物研发已跑在监管框架之前。
正文
Over 200 AI-designed drugs are now in clinical trials worldwide. Not a single one has been FDA-approved.
The FDA just launched a pilot program to work out how it should even evaluate AI-generated evidence in drug submissions, selecting 10 companies for an expedited, interactive review process.
The drugs got ahead of the regulatory framework. That's the actual state of AI pharma right now.
来源：@kimmonismus · x.com